Get it on Google Play

PepGen advances DM1 drug to highest dose after safety review

August 6, 2026 7:30 AM EDT Send to a Friend
PepGen Inc. (Nasdaq: PEPG) said an independent Data and Safety Monitoring Board (DSMB) has recommended advancing its Phase 2 FREEDOM2-DM1 ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login